Business
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fat (commonly known as a "double chin"). This innovative injectable drug is designed to dramatically improve patient comfort by utilizing a novel biological mechanism that minimizes the pain and swelling commonly associated with existing treatments.
About this update from Nano Labs Ltd
[{"type":"text","content":"— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling— Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies— AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market","length":327,"tagName":"p"},{"type":"text","content":"SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fat (commonly known as a "double chin"). This innovative injectable drug is designed to dramatically improve patient comfort by utilizing a novel biological mechanism that minimizes the pain and swelling commonly associated with existing treatments.","length":533,"tagName":"p"},{"type":"image","alt":"AMI Pharm (PRNewsfoto/AMI Pharm)","displaySize":"","headline":null,"caption":"AMI Pharm (PRNewsfoto/AMI Pharm)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/e1a5927ae898aa0a4db6525af1fb31ba"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Q89.c_QIKB5Ypz5Pdt0hGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e1a5927ae898aa0a4db6525af1fb31ba","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2744184/AMI_Pharm_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"A Paradigm Shift in Fat Reduction Therapy","length":41,"tagName":"p"},{"type":"text","content":"Currently, the only FDA-approved drug for localized fat reduction is based on deoxycholic acid, which destroys fat cells through necrosis—a process that induces inflammation and leads to significant side effects such as pain, bruising, and prolonged swelling. In contrast, AYP-101 is uniquely engineered to eliminate fat through apoptosis, a natural and controlled form of programmed cell death that does not trigger inflammation.","length":430,"tagName":"p"},{"type":"text","content":"This non-cytolytic mechanism offers a gentler, more tolerable alternative, potentially eliminating the need for social downtime and offering a safer, more comfortable experie...